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Introduction
Primordial dwarfism denotes extreme linear growth impair-
ment from early gestation. When severely reduced head size is 
also seen, primordial dwarfism is said to be microcephalic. This 
is generally taken to imply a global problem with either cellular 
or organismal growth and contrasts with primordial dwarfism in 
which the head size is relatively preserved, which is more likely to 
be accounted for by a more tissue-selective problem, affecting, for 
example, long bone growth (1).
Many human genetic defects have now been described as 
underlying microcephalic primordial dwarfism. These may affect 
endocrine growth regulation by impairing production or action of 
IGF-1 (2, 3); however, most mutations reported to date affect cell-
autonomous growth. Some clustering of defects according to the cel-
lular structure or process affected is apparent. For example, microce-
phalic primordial dwarfism can result from defects in genes involved 
in the licensing of DNA replication, in centrosome function, or in 
DNA damage response and repair pathways (reviewed in ref. 4).
In keeping with the known roles of the defective genes, some 
syndromes feature a characteristic profile of chromosomal insta-
bility or impaired DNA damage repair. Some components of the 
syndromes cannot easily be explained by known functions of the 
affected gene, however. An example is the severe insulin resis-
tance described in pericentrin deficiency (5). This usually appears 
during the first decade of life and is associated with severely fatty 
liver, elevated blood triglyceride levels, and diabetes, recapitu-
lating in severe form the pandemic metabolic syndrome. Similar 
metabolic abnormalities are seen with milder growth impair-
ment in both Bloom syndrome (6) and Werner syndrome (7), each 
caused by loss of a DNA helicase, and without growth impairment 
in patients with a heterozygous polymerase-inactivating mutation 
in DNA polymerase δ (8). However despite increasing evidence of 
a link between impaired DNA replication and/or damage respons-
es and severe insulin resistance, the underlying mechanisms link-
ing these remain unclear.
Results
A novel syndrome of primordial dwarfism. We identified 2 female 
patients with similar syndromes (details in Supplemental Mate-
rial and Methods; supplemental material available online with this 
article; doi:10.1172/JCI73264DS1). The shared features are (a) 
severe primordial dwarfism, with facial dysmorphism, including 
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were identified; however, 3 genes, NSMCE2, RUSC1, and WDR36, 
harbored compound heterozygous variants. Detailed analysis 
of these genes in large human populations, and prior functional 
studies, suggested only the NSMCE2 variants to be plausible can-
didates to cause the observed phenotype (details in Supplemental 
Appendix). NSMCE2 contained compound heterozygous frame-
shift mutations: c.345delT (p.Ser116Leufs*18), inherited from the 
proband’s mother, and c.700_701insAGGG (p.Ala234Glufs*4), 
inherited from the patient’s father (Figure 1H). Both mutations 
were absent from 1,092 individuals from the 1000 Genomes 
Project Consortium (9) and 4,190 internal control exomes and 
genomes. The p.Ala234Glufs*4 was also absent from 6,250 indi-
viduals from the NHLBI GO Exome Sequencing Project, while the 
p.Ser116Leufs*18 mutation was found in heterozygous form in 2 of 
the 6,250 individuals (allele frequency 0.00016) (details in Meth-
ods and Supplemental Table 2).
P2 was the only child of unrelated parents of European ancestry 
from the Brittany region of northwest France. Sanger sequencing of 
NSMCE2 in P2 revealed the same 2 frameshift mutations found in P1. 
Her mother was heterozygous only for the p.Ala234Glufs*4 muta-
tion, while her father was heterozygous for the p.Ser116Leufs*18 
mutation, confirming P2 to be a compound heterozygote (Figure 
1L). Although the families of P1 and P2 have no known shared ances-
try, genotyping of 21 SNPs and 2 microsatellites within the linkage 
a small jaw and prominent midface (Figure 1, A–G and I–K); (b) 
extremely insulin resistant diabetes, fatty liver, and hypertriglyc-
eridemia developing in childhood; and (c) primary gonadal failure. 
Both patients had normal karyotypes. Patient 1 (P1) had evidence 
of a mild excess of chromosome breaks in lymphocyte culture at 
several stages in her childhood, but diagnostic testing for Bloom 
syndrome and Fanconi anemia was normal. The degree of chro-
mosome damage reported reduced with time and, by the age of 
16.9 years, no excess chromosome damage could be detected. No 
similar cytogenetic studies of P2 were performed. Neither patient 
had any history of cancer, bone marrow dysfunction, nor any overt 
clinical evidence of accelerated ageing. P2 was congenitally blind, 
reportedly due to bilateral retinal detachment, and died suddenly 
at 33 years old of a sudden cardiovascular event.
Identification of NSMCE2 mutations. P1 was born to unrelated 
parents of European ancestry from Wales and had 4 unaffected 
siblings. We hypothesized either biallelic, likely compound het-
erozygous, loss-of-function mutations or a de novo dominant 
mutation, affecting a critical growth-related gene. Exome-wide 
sequences of P1 and her parents were analyzed using DeNovo-
Gear (described in Methods) to look for de novo mutations in P1 
and to search for genes with compound heterozygous or homozy-
gous rare mutations plausibly affecting protein function (details 
in Methods and Supplemental Figure 1). No rare de novo variants 
Figure 1. A syndrome of primordial dwarfism and extreme insulin resistance associated with compound heterozygous NSMCE2/MMS21 frameshift 
mutations. (A–G) P1 at (A) 4 months, (B) 2 years, (C) 12 years, and (D) 24 years of age. (E) Profile at 12 years showing prominent midface and small lower 
jaw. (F) Severe axillary acanthosis nigricans with skin tags. (G) Severe acanthosis nigricans on the lateral neck. (H) Pedigree diagram for P1 with adult 
heights, where available, shown in meters. NSMCE2 genotypes are shown as WT, 116fs (p.Ser116Leufs*18), and 234fs (p.Ala234Glufs*4). (I–K) P2 shown at 
27 years old. (I) Whole-body appearance illustrating dwarfism and paucity of adipose tissue and muscle. (J) Profile showing prominent midface and small 
lower jaw. (K) Detail of arm at antecubital fossa showing severe acanthosis nigricans. (L) Pedigree diagram for P2. Written, informed consent was obtained 
from patients or their families for publication of these images.
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sponds to NSMCE2/MMS21 (10–12). The NSMCE2 gene product 
is often named MMS21 due to its original identification in a Sac-
charomyces cerevisiae screen for mutants sensitive to the alkylat-
ing agent methane methylsulphonate (MMS) (13). The Schizosac-
charomyces pombe gene is Nse2. Here, we refer to the protein as 
NSMCE2/MMS21, or NSMCE2 in figures.
The function of SMC5–6, although critical for survival in all 
organisms studied, is not well understood. Current evidence, 
particularly from hypomorphic yeast mutants, has defined roles 
in DNA replication and recombination, including the facilitation 
of homologous recombination repair (HRR), through aiding of 
resolution of topologically complex DNA intermediates. Failure 
to complete HRR may lead to checkpoint activation and apoptosis 
or to catastrophic failure to untangle highly catenated, intercon-
nected chromosomes.
NSMCE2/MMS21 possesses a Siz/PIAS RING (SP-RING) 
domain toward its C terminus with SUMO E3-ligase activity. Sev-
block encompassing NSMCE2 (chr8: 126104083–1263936) con-
firmed that both patients inherited the same 2 rare haplotypes within 
a region greater than 510 kb, one containing the p.Ser116Leufs*18 
mutation, the other p.Ala234Glufs*4. This suggests shared com-
mon ancestral haplotypes: one, greater than 510-kb long, contain-
ing p.Ser116Leufs*18, estimated to have arisen 283 generations 
(less than 8,500 years) ago, and the other, greater than 339-kb long, 
containing p.Ala234Glufs*4, estimated to have arisen 150 gen-
erations (less than 4,500 years) ago, based on the locus-specific 
recombination rate. Neither haplotype nor the p.Ser116Leufs*18 nor 
p.Ala234Glufs*4 mutations were present in a sample of 54 controls 
from Great Britain (Methods and Supplemental Table 3).
NSMCE2/MMS21 and SMC5–6. NSMCE2 encodes a protein 
component of the heteromultimeric structural maintenance of 
chromosomes 5–6 (SMC5–6) complex (10). It consists of 2 core 
SMC components (SMC5 and SMC6) and, in humans, 4 non-SMC 
elements often designated as NSE1-4, among which NSE2 corre-
Figure 2. Expression and auto-SUMOylation of NSMCE2/MMS21 frameshift mutations. (A) Schematic showing positions of patient mutations 
with respect to the SP-RING SUMO-ligase domain. (B) Schematic of NSMCE2/MMS21 showing disruption of α helix α8 (residues 223–240) by the 
p.Ala234Glufs*4 mutation. Alignment of human WT (Mms21_human) and p.Ala234Glufs*4 (A234E) MMS21/NSMCE2 based on the crystal structure of  
S. cerevisiae Mms21 (Mms21_sc; PDB entry: 3HTK; chain C). The 14 amino acids removed by the mutation are marked in boldface. Numbering and secondary 
structure of S. cerevisiae Mms21 are displayed. The position of the mutation in human MMS21/NSMCE2 is displayed below the sequences. (C) NSMCE2 
expression in dermal fibroblasts from P1 assessed using immunoblotting of increasing amounts of whole-cell extract compared with WT fibroblasts. (D) 
Similar immunoblotting of whole-cell extract from P1 LCLs. (E) Auto-SUMOylation activity of Myc-tagged WT, SUMO LD, and naturally occurring mutant 
NSMCE2/MMS21 following coexpression with GFP-SUMO1 (upper panels). Auto-SUMOylation was detected following IP using anti-Myc and blotting (WB, 
Western blot) using anti-GFP antibodies. IgHC, immunoglobulin heavy chain. The lower panel shows relative amounts of immunoprecipitated Myc-
NSMCE2. The p.A234Efs*4 mutation appears not to affect protein gel migration under these conditions, unlike p.S116Lfs*18 (Supplemental Figure 3). (F) 
Quantification of recovered Myc-NSMCE2-GFP-SUMO conjugates by densitometry. Data represent mean ± SD. (n = 3). *P ≤ 0.05 (unpaired, 2-tailed t test).
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Figure 2, A and B). mRNA levels of NSMCE2/MMS21 were 50% 
of WT in dermal fibroblasts, although near normal in LCLs. cDNA 
sequencing showed no evidence of the p.Ser116Leufs*18 species, 
suggesting that its mRNA is unstable (Supplemental Figure 2, C 
and D). We did not detect truncated NSMCE2/MMS21 protein. 
However on heterologous overexpression of a Myc-tagged ver-
sion of NSMCE2/MMS21 carrying the p.Ser116Leufs*18 muta-
tion in A549 cells, a low level of the truncated protein could be 
seen on immunoblotting (Supplemental Figure 3A). Although 
p.Ala234Glufs*4, in contrast, was detected at levels close to those 
of overexpressed WT NSMCE2/MMS21, its levels decayed more 
quickly than those of WT NSMCE2/MMS21 after overexpression 
in HeLa cells treated with cycloheximide, consistent with reduced 
protein stability (Supplemental Figure 2E).
To determine the impact of the mutations on the SUMO-ligase 
activity of NSMCE2/MMS21, we assessed auto-SUMOylation 
of Myc-tagged NSMCE2/MMS21 ectopically coexpressed with 
GFP-SUMO1 in A549 cells. NSMCE2/MMS21 species were 
immunoprecipitated using anti-Myc beads, and the SUMO-
modified versions of NSMCE2/MMS21 were detected by West-
eral targets for this have been documented in various organisms 
(14–16), including NSMCE2/MMS21 itself, SMC5, and SMC6. 
Yeast strains with loss of Mms21 SUMO-ligase activity are viable, 
but exhibit increased genomic instability (14, 17), while SUMO-
ligase activity in mammalian cell lines is required for normal 
responses to some forms of DNA damage (15, 16).
Cellular phenotype associated with NSMCE2 hypomorphism. 
The p.Ser116Leufs*18 mutation occurs between the N-terminal 
helix bundle and the SP-RING domain and introduces 18 unstruc-
tured amino acids, while the p.Ala234Glufs*4 mutation lies at the 
C terminus of the domain, removing the 14 C-terminal amino 
acids of the protein (Figure 2A) and thereby disrupting the C-ter-
minal α helix formed by residues 223–240 (ref. 18 and Figure 2B). 
Western blotting of Epstein Barr virus–transformed lymphoblas-
toid cells (LCLs) (Figure 2C) and primary dermal fibroblasts (Fig-
ure 2D) from P1 revealed severely depressed levels of full-length 
NSMCE2. Mild underexpression of SMC5 and SMC6 was also 
observed in whole-cell and chromatin-enriched extracts from 
P1-derived LCLs compared with WT, suggestive of instability of 
the core SMC5–6 protein complex in these cells (Supplemental 
Figure 3. HU-induced nuclear abnormalities in primary fibroblast cells are rescued by expression of WT but not SUMO LD NSMCE2/MMS21. Typical 
micrographs of binucleated dermal fibroblasts showing (A and B) MN or (C) NPB. Scale bars: 5 μm. (D) Increased frequency of MN or (E) NPB in Cyt-B–
treated dermal fibroblasts from P1 relative to age-matched healthy controls (WT) following a 4-hour block in 1 mM HU. (F) DOX-induced expression of 
WT or SUMO LD NSMCE2/MMS21 in P1 or control dermal fibroblasts (WT fibroblasts, 2 samples shown) analyzed by immunoblotting with antibodies 
specific to human NSMCE2/MMS21 (WB: α-NSMCE2). Asterisk indicates a crossreactive band that serves as an internal loading control. (G and H) DOX-
induced ectopic expression of WT NSMCE2/MMS21 reduces frequencies of MN (G) and NPB (H) to levels seen in control cells. In contrast, DOX-induced 
ectopic expression of NSMCE2/MMS21 (LD) significantly increases levels of both MN (G) and NPB (H). Frequencies of MN per 100 or NPB per 1,000 
binucleated cells are shown for each experimental condition, as indicated. All bar graphs represent mean ± SEM (n = 4). *P < 0.05; **P < 0.01;  
***P < 0.001 (unpaired 1-tailed t test).
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p.Ala234Glufs*4 mutant exhibited a level of auto-SUMOylation 
similar to that of WT NSMCE2/MMS21 under these conditions 
(Figure 2, E and F).
Having confirmed that cells from P1 were severely hypo-
morphic for NSMCE2/MMS21, we next characterized the associ-
ated cellular phenotype. The frequencies of micronuclei (MN) and 
nucleoplasmic bridges (NPB) in cytokinesis-blocked binucleated 
cells (Figure 3, A–C) are widely used as indicators of chromosomal 
ern blotting with anti-GFP (Figure 2, E and F, and Supplemental 
Figure 3B). A previously validated SUMO-ligase-deficient (LD) 
version of NSMCE2/MMS21 with mutations in the SP-RING 
(p.Cys185Ala and p.His187Ala) (19) was used as a negative con-
trol. Consistent with its reduced expression and lack of SP-RING 
domain, auto–SUMO-ligase activity of p.Ser116Leufs*18 was 
virtually undetectable. As expected, auto-SUMOylation activ-
ity of the LD variant was also severely reduced. In contrast, the 
Figure 4. Increased micronucleus formation, impaired S phase progression, and increased SCE in LCLs with NSMCE2/MMS21 mutations. (A) Binucleates 
in LCLs from WT, P1, and from a Bloom syndrome patient, either untreated (Unt) or following repeated exposure to HU (50 μM/d for 4 days). (B) HU-induced 
MN formation in Cyt-B–induced binucleate LCLs. (C) BrdU flow cytometry profiles from WT and P1 LCLs either untreated or following treatment with low-
dose HU (250 μM). S phase content (boxed area) following a BrdU pulse 30 minutes prior to each time point is shown. (D) Normalized total S phase content 
compared with that of untreated cells at each time point. Means ± SD are shown (n = 3). (E) BLM foci formation in P1 LCLs relative to WT following treat-
ment with HU (1 mM for 16 hours) or IR (10 Gy for 16 hours). (F) BLM foci formation in primary dermal fibroblasts from P1 compared with WT following HU 
exposure (1 mM for 24 hours). (G) UV radiation–induced SCEs in WT and P1 LCLs compared with untreated cells. These effects, although significant, were not 
as profound as those observed in BLM patient LCLs, which exhibited 23 ± 6 SCEs/metaphase in untreated cells and 38 ± 4 SCEs/metaphase following UV 
irradiation. *P < 0.05 (unpaired t test).
Downloaded August 11, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI73264.
The Journal of Clinical Investigation R e s e a R c h  a R t i c l e
6 jci.org
damage and instability (20). Typically, MN develop when errors 
in chromosome segregation during mitosis occur from acentric 
fragments of chromosomes and/or anaphase-lagging whole chro-
mosomes, while NPB form when centromeres of dicentric chro-
mosomes are drawn to opposite poles at anaphase or by telomere 
shortening. When the actin polymerization inhibitor cytochalasin 
B (Cyt-B) is used to inhibit cytokinesis, observed MN are derived 
from events in the preceding S phase. Given the role suggested for 
SMC5–6 in resolution of HRR intermediates, we thus assessed the 
frequencies of MN and NPB in Cyt-B–induced binucleated dermal 
fibroblasts from P1.
The basal frequency of MN was significantly higher in binu-
cleated dermal fibroblasts from P1 relative to WT, although NPB 
frequencies in these cells were indistinguishable (Figure 3, D and 
E). We next assessed these following treatment with hydroxyurea 
(HU), a potent inducer of replication fork stalling and collapse. 
Following HU, binucleated dermal fibroblasts from P1 showed 
higher frequencies of both MN and NPB than WT (Figure 3, D 
and E). Doxycycline-induced (DOX-induced) expression of WT 
NSMCE2/MMS21 (Figure 3F) significantly reduced the frequency 
of MN and NPB in P1 binucleates. In contrast, expression of the 
LD version of NSMCE2/MMS21 markedly increased their fre-
quency (Figure 3, G and H).
LCLs derived from P1 exhibited a similar phenotype. There 
was an approximately 1.8-fold increase in spontaneously binucle-
ated cells compared with WT, an increase also observed in Bloom 
syndrome LCLs. This increase was exacerbated in both P1 and 
Bloom syndrome LCLs following exposure to repeated treatment 
with low concentrations of HU (once daily for 4 days) (Figure 4A). 
Reminiscent of P1 fibroblasts, we also observed modestly elevated 
spontaneous and HU-induced MN formation in binucleates gen-
erated by Cyt-B treatment (Figure 4B).
Yeast SUMO-LD mutants of the NSMCE2/MMS21 ortholog 
and mutations in smc6 are associated with replication delay and 
accumulation of unresolved hemi-catenated, X-shaped DNA 
molecules (21, 22). BrdU pulse chase analysis of asynchronously 
growing P1-derived LCLs did not reveal a significant difference in 
S phase progression rate compared with WT (Supplemental Fig-
Figure 5. Modeling of NSMCE2/MMS21 deficiency in zebrafish. Injection of splice-site MOs targeted to Nsmce2 markedly reduce body size compared with 
that of control-injected or uninjected WT embryos. (A) Representative images of some arbitrarily defined length categories: normal, –1 to 1 SD; short, –1 
to –2 SD; dwarf, –2 to –3 SD; severe, < –3 SD. (B) Quantification of length of MO-injected zebrafish (uninjected, n = 18; control, n = 28; MO, n = 37). (C–E) 
Coinjection of WT human NSMCE2/MMS21 mRNA (WT rescue) with nsmce2-targeting MOs attenuated the dwarf phenotype observed in the nsmce2 
morphant alone (morph). In contrast, coinjection of either (C) human NSMCE2/MMS21 S116Lfs*18, (D) human NSMCE2/MMS21 A234Efs*4, or (E) SUMO LD 
human NSMCE2/MMS21 mRNAs together with nsmce2-targeting MOs did not affect the severity of the dwarf phenotype. Uninj, uninjected; con, control. 
Graphs show SD scores relative to those of uninjected WT zebrafish embryos from the same mating. n = 12–15 for each condition. P values were calculated 
by ANOVA with post-hoc Tukey test; *P < 0.05, **P < 0.01, ***P < 0.001.
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ure 4). However, we did see impaired recovery of DNA replica-
tion following acute treatment with a low concentration of HU in 
P1-derived LCLs compared with WT (Figure 4, C and D).
Bloom syndrome helicase (BLM), which is disrupted in Bloom 
syndrome, plays a fundamental role in resolution of converging 
Holliday junctions during HRR. Consistent with synthetic inter-
action between the BLM ortholog in yeast (Sgs1) and mutation 
of the NSMCE2/MMS21 ortholog, we observed an impairment in 
BLM foci formation in P1-derived LCLs both in response to rep-
lication stress induced by HU and in response to ionizing radia-
tion (IR) (Figure 4E), in contrast with WT. A similar impairment 
of BLM focus formation was seen in patient fibroblasts exposed 
to HU (Figure 4F). Moreover, following UV treatment, another 
potent means of replication fork stalling, we observed significant 
elevation in UV-induced sister chromatid exchanges (SCE) in P1 
LCLs compared with WT, consistent with the impaired ability to 
form BLM foci of these cells (Figure 4G). Collectively, these data 
are consistent with a failure of NSMCE2/MMS21-mutated patient 
cells to complete cell division effectively following chronic repli-
cative stress. In contrast, P1 LCLs showed no hypersensitivity to 
camptothecin or mechlorethamine, unlike BLM-deficient cells 
(Supplemental Figure 5, A–C). As HRR-defective cells are sensi-
tive to killing by both these agents, this suggests that DNA repair 
per se is not completely deficient as a result of this hypomorphic 
defect in NSMCE2/MMS2.
Modeling of NSMCE2/MMS21 deficiency in zebrafish. As no 
Nsmce2 knockout mouse has been reported to date, we used 
zebrafish to test the consequence of loss of Nsmce2 function in 
vivo. We utilized a cocktail of 2 splice-site anti-sense morpholi-
nos (MOs) to deplete the zebrafish NSMCE2/MMS21 ortholog, 
reducing its mRNA levels in the morphant to approximately 20% 
of those of control MO-injected embryos (Methods and Supple-
mental Figure 6). This markedly reduced body size compared 
with uninjected and control MO-injected embryos (Figure 5, 
A and B). From 5% to 15% of the nsmce2/mms21 MO-injected 
embryos exhibited an extreme phenotype including body curva-
ture and increased mortality; however, the majority of embryos 
were grossly normal morphologically. Coinjection of human WT 
NSMCE2 mRNA with zebrafish nsmce2/mms21-targeting MOs 
attenuated the dwarf phenotype observed in the nsmce2 mor-
phant alone, with coinjected embryos not significantly different 
in length from those injected with control MO alone (Figure 5, 
C–E). In contrast, coinjection of either mRNA variant identified 
in the patients failed to rescue the nsmce2/mms21 morphant phe-
notype (Figure 5, C and D).
In keeping with findings in mammalian cells, levels of GFP-
tagged mutant NSMCE2/MMS21 protein decayed much more rap-
idly than those of GFP-tagged WT NSMCE2/MMS21, despite high 
and equivalent levels of mRNA being detected after injection, sug-
gesting impaired translation and/or instability of the mutants (Sup-
plemental Figure 7). Collectively, these experiments confirm the 
specificity of the MO effect and suggest that the NSMCE2/MMS21 
frameshift mutations identified in the patients lead to loss of func-
tion. Interestingly, coinjection of a SUMO LD version of NSMCE2/
MMS21 also failed to rescue nsmce2 morphants (Figure 5E) 
coincident with reduced expression of this GFP-tagged protein, as 
seen for the other mutants (Supplemental Figure 7).
Discussion
Our findings demonstrate association between compound hetero-
zygosity for rare frameshift mutations in NSMCE2/MMS21 and a 
syndrome of primordial dwarfism, extreme insulin resistance, and 
primary gonadal failure. One of the mutations, p.Ser116Leufs*18, 
removes the whole SP-RING domain, is nearly undetectable in 
primary cells, has undetectable SUMO autoligase activity, and 
is unable to rescue the zebrafish morphant phenotype on reex-
pression. The second mutation, p.Ala234Glufs*4, in contrast, is 
predicted to remove only 14 amino acids distal to the SP-RING 
domain, is well expressed from a strong promoter in heterolo-
gous cellular systems, and exhibits normal SUMO autoligation 
after overexpression. The direct evidence that it is a loss-of-func-
tion mutation thus rests on the extremely low level of full-length 
NSMCE2/MMS21 observed in primary fibroblasts and LCLs from 
P1 and on the failure of the reexpressed mutant to rescue the 
dwarfism of nsmce2/mms21 morphant zebrafish, which we sug-
gest is due to reduced stability of the mutant protein. These data 
establish that the patients described are severely hypomorphic 
for NSMCE2/MMS21 and demonstrate that this results in severe 
dwarfism, insulin resistance and primary gonadal failure, with 
mild evidence of spontaneous chromosomal instability.
The SMC5–6 complex is structurally closely related to cohe-
sion (SMC1–3) and condensin (SMC2–4). Although cohesin and 
condensin have relatively well characterized roles in mitosis, 
respectively, holding sister chromatids in apposition or mediating 
the premitotic condensation of chromosomes (23), the function of 
the SMC5–6 complex is less well understood. The accumulation 
of aberrant DNA intermediates with hypofunction of the yeast 
NSMCE2/MMS21 ortholog (21, 22) and synthetic lethality in 
combination with mutations in the topoisomerase II ortholog (24) 
argues for a role in resolving topologically complex intermediates 
of HRR. Inability to resolve these intermediates is particularly 
harmful in the context of restarting stalled or collapsed DNA rep-
lication forks, which appear, for example, when the DNA template 
is damaged or the nucleotide pool depleted (21, 22, 25).
The phenotype of patient cells, namely impaired ability to recov-
er from replication stress leading to genomic instability both at base-
line and in response to induced replication fork stalling, is in keeping 
with a role for NSMCE2/MMS21 in resolving complex DNA struc-
tures and is consistent with findings in yeast, avian, and mammalian 
cells (e.g., refs. 11, 14–16, 26). We also demonstrate a mild increase in 
SCE following UV irradiation of patient LCLs; however, this increase 
is much smaller than that seen in Bloom syndrome. Such an aberrant 
“hyperrecombination” phenotype has also been reported in chick 
DT40 cells with NSMCE2/MMS21 deficiency (26).
The precise role of the SUMO-ligase activity of NSMCE2/
MMS21 is not fully delineated. Several targets have been docu-
mented in various organisms (14–16). As well as NSMCE2/MMS21, 
SMC5, and SMC6, these include other proteins with important 
roles in DNA damage sensing and chromosome stability, includ-
ing KU70, SCC1, and the telomeric proteins TRF1 and TRF2. Stud-
ies in avian (26) and mammalian (16, 27) cells have suggested that 
loss of the SUMO-ligase activity of NSMCE2/MMS21 orthologs 
leads to genomic instability. Our data now extend these findings. 
The increased MN and NPB seen after reexpression of a SUMO 
LD variant of NSMCE2/MMS21 in patient fibroblasts suggest that 
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cells further argues for commonality between Bloom syndrome 
and the syndrome we describe. On the other hand, our patients 
did not have cardinal clinical features of either Bloom or Werner 
syndrome, and the level of increase of SCE was far lower here than 
in Bloom syndrome. The detailed cellular phenotype of cells with 
polymerase domain mutations of DNA polymerase δ, the predom-
inant lagging strand DNA polymerase, has yet to be reported.
Although it is tempting to equate whole-body insulin sensitiv-
ity to cell-autonomous insulin sensitivity, this is commonly mis-
leading. Maintenance of whole-body insulin sensitivity requires 
not only intact cellular insulin signaling pathways, but also normal 
size and function of key insulin-responsive tissues — particularly 
adipose tissue, muscle, and liver. Indeed, most Mendelian forms 
of insulin resistance are accounted for by mutations, not in genes 
involved directly in insulin signaling, but rather those involved in 
adipose tissue development or function (34). It is thus plausible that 
genetic defects severely impairing mitosis or response to replication 
stress ultimately produce insulin resistance through progressive 
failure to maintain one or more insulin responsive tissues, a notion 
in keeping with the paucity of adipose tissue and muscle we observe 
in our patients. This idea remains to be validated; however, there 
is growing interest in the link between pandemic forms of insulin 
resistance, oxidative stress, and thereby DNA damage (28), and so 
in vivo modeling of severe NSMCE2/MMS21 hypomorphism may 
not only aid understanding of this rare and extreme condition, but 
may also offer wider, paradigmatic insights into common disease.
Methods
Exome sequencing. Genomic DNA was extracted from blood leukocytes 
and prepared as described previously (35) for capture. Amplification 
and sequencing were performed on the Illumina Genome Analyzer II 
(index case) or Hi-Seq platform (parents) (Illumina) as 54- or 75-bp 
paired-end reads respectively. BWA software package 0.5.9, Picard 
v1.46, SamTools v0.1.16 (36), Dindel v1.01 (37), Genome Analy-
sis Toolkit (GATK) v1.1-20 (38), and Variant Effect Predictor (VEP) 
v2.1 (39) were used to map sequence reads to the genome reference 
sequence (NCBI build 37), to calculate read quality, to call single 
nucleotide variants (SNVs) and insertion/deletions, and to annotate 
against Ensembl build 64. Variants were filtered to include only those 
with a minimum depth of 4× to a maximum depth of 1200× and were 
reported in variant calling file (VCF) format v4.1. For the index case, 
6.4 Gb of sequence was produced at a mean depth of 60, with 80.4% 
coverage at a depth greater than or equal to 10, using high mapping 
quality alignments only (i.e., mapping quality ≥ 30). Equivalent fig-
ures for the father and mother were 8.8 Gb, 95% and 86.1%, and 8.9 
Gb, 97% and 91.0% respectively. Raw exome sequence data from 
the trio are available from the European Genome-phenome Archive 
(EGAN00001101658, EGAN00001001829, EGAN00001001831).
De novo and compound heterozygous mutation analysis. Exome data 
for P1 and her parents were merged, and variants with a high posterior 
probability of being de novo (cutoff value 0.8) were extracted using 
DeNovoGear v0.5 (https://sourceforge.net/projects/denovogear/) 
(40). Python scripts were used to extract potential compound hetero-
zygous mutations. Variant annotation has previously been described in 
detail (41). Potentially causal variants identified were reconfirmed by 
Sanger sequencing of PCR products using the BigDye Terminator v3.1 
Cycle Sequencing Kit according to the manufacturer’s instructions 
SUMO-ligase activity may be required for at least some important 
functions of NSMCE2/MMS21 in higher eukaryotes. Neverthe-
less, the viability of yeast strains lacking ligase activity and the 
nonviability of strains wholly lacking the NSMCE2/MMS21 ortho-
log indicate that NSMCE2/MMS21 has other essential functions 
that are SUMO-ligase independent.
The question arises as to whether the cellular defects we 
observe account for the phenotype of the affected patients. Grow-
ing cells are subjected to a barrage of endogenously generated 
DNA damage during every cell division, arising, for example, from 
generation of reactive oxygen and nitrogen species as a by-product 
of metabolism (28), so it is plausible that reduced cellular ability to 
tolerate replicative stress and associated DNA damage is the cause 
of global growth impairment. This is mechanistically akin to the 
primordial dwarfism seen when the DNA damage-sensing kinase 
ATR (29) is mutated in Seckel syndrome.
Both patients with NSMCE2/MMS21 deficiency also exhibit 
primary ovarian failure. Primary gonadal failure is a consequence 
of defects in several other human DNA damage response compo-
nents, including ATM, NBS, BLM and members of the Fanconi 
anemia complex, presumably due to impaired meiosis and/or 
mitosis of germ cells in utero. Furthermore, the yeast ortholog of 
NSMCE2/MMS21 has been shown to be required for meiosis (30). 
The ovarian failure of the 2 patients we describe is thus potentially 
explicable through established functions of NSMCE2/MMS21. It 
remains possible, however, that NSMCE2/MMS21 serves unknown 
functions that are related to the observed phenotype, as in the case 
of genetic cohesinopathies, where important components of the 
clinical syndromes result from perturbed transcriptional regula-
tion, rather than directly to loss of cohesin’s longest established 
role in sister chromatid cohesion.
The highly insulin resistant diabetes that we report is more dif-
ficult to reconcile simply with the observed cellular defects. As our 
study ascertained patients based on the presence of severe insulin 
resistance, further work will be needed to determine confidently 
whether it is an obligate feature of NSMCE2/MMS21 loss of func-
tion in humans; however the insulin resistance in both cases was 
extreme. Although the derangement in insulin and glucose levels 
was of a similar degree to that seen with loss of insulin receptor 
function (31), the metabolic phenotype was quite distinct. Both 
our patients had severe fatty liver and dyslipidemia, which are not 
seen with insulin receptor dysfunction (32). Instead, the metabolic 
phenotype closely resembles that seen in primary disorders of adi-
pose tissue development or function (33).
A clue to the origins of the metabolic derangement we report 
may come from its resemblance to that of patients with Bloom and 
Werner syndromes (6, 7) or of patients with heterozygous poly-
merase domain mutations in DNA polymerase δ (8). Bloom and 
Werner syndromes are caused, respectively, by loss of the BLM 
(RECQL3) and WRN (RECQL2) DNA helicases, both of which play 
multiple accessory roles in resolution of complex DNA structures. 
The yeast phenotype caused by loss of the primordial ancestral 
DNA helicase that later diverged to produce WRN and BLM resem-
bles the phenotype seen with hypomorphism for the NSMCE2/
MMS21 ortholog (22). Our observation of impaired replicative 
stress–induced BLM foci formation and modestly increased lev-
els of SCE following UV irradiation in NSMCE2/MMS21 patient 
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(MBA-251, LGC Standards; ATCC) and subsequently into pSLIK-Neo 
(MBA-236, LGC Standards; ATCC) using site-specific recombination 
(Gateway LR Clonase II Enzyme Mix; Invitrogen).
SUMOylation assay. 4 × 106 A549 cells were cotransfected with 4 μg 
GFP-SUMO-1 plasmid (pEGFP–SUMO-1) and 10 μg of WT or mutant 
pCI-Neo-Myc-NSMCE2. Cells were harvested 24 hours after transfec-
tion and solubilized with immunoprecipitation (IP) buffer (50 mM Tris-
HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 25 mM NaF, 25 
mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 0.2% Triton 
X-100, 0.3% NP40, and Promega protease inhibitors cocktail) contain-
ing 20 mM N-ethylmaleimide. Myc-tagged proteins were immunopre-
cipitated using Red Anti-Myc Affinity Beads (E6654; Sigma-Aldrich). 
SUMOylation of immunoprecipitated material was detected by immu-
noblotting using anti-GFP antibody (2555; Cell Signaling).
Establishment of cell lines conditionally expressing WT or ligase-
inactive SMCE2/MMS21. 10 μg of pSLIK WT or SUMO LD NSMCE2 
plasmid, 7.5 μg of each of the packaging plasmids pMDLg/pRRE and 
pRSREV, and 5 μg of the pseudotyping pVSV-G plasmid were cotrans-
fected into HEK 293T cells on 10-cm dishes using CalPhos Mamma-
lian Transfection Kit (Clontech). The culture medium was replaced 
12 hours after transfection with BioWhittaker Ultraculture medium 
(Lonza). Viral supernatants were harvested at 24, 48, and 72 hours after 
transfection and concentrated by centrifugation in Centricon Plus-70 
Ultracel PL-100 (Millipore). Lentiviral particles were added at low MOI 
to dermal fibroblasts in the presence of 8 μg/ml of polybrene for 6 hours 
followed by selection in G418 (600 mg/ml; Sigma-Aldrich) for 3 weeks. 
Stable cell lines were maintained in the presence of 200 mg/ml G418.
Micronucleus assay. Dermal fibroblasts were grown to 70% to 80% 
confluence ± 1 mg/ml of DOX, trypsinized, resuspended, counted, and 
seeded onto glass coverslips. Twenty hours later, cells were exposed to 
1 mM HU or saline for 4 hours, followed by saline washing, and allowed 
to recover in the presence of 3 μg/ml of cytochalasin-B for 48 hours, 
fixed with 4% paraformaldehyde for 15 minutes at room temperature, 
permeabilized in 0.05% Triton X-100, and stained with Actin-stain 
488 Phalloidin (Cytoskeleton Inc.) and DAPI (Invitrogen) in PBS. 
Cells were examined at ×100 magnification using a wide-field fluores-
cence microscope (BX61; Olympus). Scoring criteria were according to 
Fenech (20), using 1,000 binucleates per experimental condition.
For micronucleus studies in LCLs, cells were treated with 1 mM HU 
for 4 hours; HU was washed out and cells cultured in cytochalasin-B for 
24 hours prior to harvesting to generate binucleates. Indirect immuno-
fluorescence using anti–β-tubulin antibodies (Santa Cruz Biotechnol-
ogy Inc.) and counterstaining with DAPI was employed to visualize the 
cytoplasm and to enable unbiased identification of binucleated cells.
FACS analysis. LCLS were treated with 250 μM HU for up to 6 hours, 
and the proportion of cells in S phase was measured using BrdU pulse-
mediated flow cytometry. Cells were pulse labeled with 20 μM BrdU 
20 minutes prior to harvesting, then fixed in ice-cold 70% ethanol for 
24 hours and resuspended in PBS containing 0.5% Tween-20, 10 μg/ml 
propidium iodide, and 500 μg/ml RNaseA. FITC-conjugated anti-
BrdU (clone 44, BD) was used for detection of S phase cells following 
HCl denaturation. To monitor the rate of S phase progression LCLs 
were pulse labeled for 30 minutes with BrdU, washed in PBS, and 
then incubated in complete medium supplemented with Colcemid 
(100 μg/ml). Cells were harvested at 2-hour intervals and processed 
as described above. Data were collected using a BD FACS Canto and 
analyzed with FACS DIVA software.
(Applied Biosystems; Life Technologies) and run on ABI 3730 DNA 
Sequencers (Applied Biosystems). Sequence analysis was performed 
using the Mutation Surveyor software package v2.3 (LLC; SoftGenet-
ics). For P2, all exons and exon-intron boundaries of NSMCE2 were 
sequenced using Sanger sequencing as above (for primer sequences, 
see Supplemental Table 1).
Haplotype analysis. Twenty-four SNPs were selected from Hap-
Map release 27 (42) to capture the variation within the 2 linkage blocks 
surrounding the p.Ser116Leufs*18 and p.Ala234Glufs*4 mutations 
(chr8: 125672673–126874287). These were genotyped along with 
the microsatellites D8S1179 and D8S266 in both probands, their 
families and 54 ethnically matched controls predominantly from the 
west of Great Britain from the 1000 genomes GBR panel (http://
www.1000genomes.org/about#ProjectSamples). SNP genotyping 
was performed using the iPLEX Gold Assay (Sequenom Inc.) accord-
ing to the manufacturer’s instructions, while microsatellites were 
amplified by PCR using FAM-labeled forward primers, diluted, mixed 
with CC5 Internal Lane Size Standard 500 (Promega),and run on an 
ABI 3730 DNA Analyser (Applied Biosystems). Allelic determination 
was undertaken using GeneMapper software (Applied Biosystems). Of 
the 24 SNPs, 3 were monomorphic in our data set.
Analysis was performed on the 21 polymorphic SNPs using SHA-
PEIT2 (http://www.shapeit.fr/) to phase the genotypes and calculate 
the most likely haplotypes, and the microsatellite markers were used 
to further define the haplotypes where ambiguous.
Patient cell culture. Epstein Barr virus–transformed LCLs were 
generated from primary lymphocytes using standard procedures and 
maintained in RPMI 1640 supplemented with l-glutamine, antibiot-
ics (penicillin streptomycin), and 15% FBS. Bloom syndrome LCLs 
(GM09960) from a patient with a homozygous 6-bp deletion/7-bp 
insertion (6-bp del/7-bp ins) at nucleotide 2,281 of the open-reading 
frame of the RECQL3 gene were from Coriell Cell Repository. Dermal 
fibroblasts were grown from skin biopsies using standard procedures, 
maintained in MEM supplemented with L-glutamine, antibiotics 
(penicillin streptomycin), and 15% FBS.
NSMCE2/MMS21 expression analysis. Endogenous NSMCE2 pro-
tein was detected in ureasonicated (15 seconds 30% amplitude using a 
micro-tip; Sigma-Aldrich) whole-cell extracts (9 M urea, 50 mM Tris-
HCl, pH 7.5, 10 mM 2-mercaptoethanol) via immunoblotting with 
polyclonal rabbit antibody (Ab N2-19) raised against full-length GST-
NSMCE2 protein (19).
Generation of mammalian and lentiviral expression vectors. Expression 
vectors pCI-Neo-Myc harboring WT or the SUMO LD mutant C185A/
H187A (19) were from Elaine Taylor and Alan Lehmann (Genome 
Damage and Stability Centre). p.S116fsLeufs*18 and p.Ala234Glufs*4 
mutants were generated by site-directed mutagenesis of WT Myc-tagged 
NSMCE2 using the QuikChange XL II protocol (Agilent) and the follow-
ing mutagenesis primers: p.S116fsLeufs*18: sense primer, 5′-TTTTTG-
GCTTTACAGAGCAAGAATCTGATGCAGACTTTCAAAATAAT-3′ 
and antisense primer, 5′-ATTATTTTGAAAGTCTGCATCAGATTCTT-
GCTCTGTAAAGCCAAAAA-3′; p.Ala234Glufs*4: sense primer, 
5′-GGATGAAGCACTTAGAAGGGAGGGCAATTGAGAACCATAA-
CAAG-3′ and antisense primer, 5′-CTTGTTATGGTTCTCAATT-
GCCCTCCCTTCTAAGTGCTTCATCC-3′. To construct the DOX-
inducible lentiviral expression vectors pSLIK-Neo-NSMCE2 (WT) and 
pSLIK-NSMCE2 (LD), coding regions of human NSMCE2 or the LD 
mutant were amplified and cloned into the entry vector pEN-Tmcs 
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Statistics. All numerical data were analyzed using parametric sta-
tistical tests, namely Student’s t test or ANOVA with post hoc Tukey’s 
testing, as appropriate. All tests used and thresholds for significance 
are indicated in figure legends.
Study approval. This study was approved by the UK National 
Research Ethics Committee. Written informed consent was obtained 
from all participants or their parents.
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BLM foci. LCLs were swollen in 75 mM KCl (10 minutes), immobi-
lized on poly-L-lysine–coated slides by cytospinning (Cytospin; Shan-
don), fixed with 3% PFA and 2% sucrose in PBS, permeabilized using 
0.1% Triton X-100 in 5% BSA-PBS for 2 minutes, blocked (5% BSA-
PBS for 10 minutes) and incubated with goat polyclonal anti-BLM 
(clone C-18, #sc7790; Santa Cruz Biotechnology Inc.) at 1:50 dilu-
tion in 5% BSA for 1 hour. Cells were counterstained with the appro-
priate FITC-conjugated secondary antibody and the nuclei stained 
with DAPI. Primary fibroblasts were fixed with methanol (–20°C for 
20 minutes) and BLM foci detected using anti-BLM antibodies (2742; 
Cell Signaling). Slides were analyzed using the Zeiss AxioPlan plat-
form and images captured using Simple PCI software.
UV-induced SCE. LCLs were UV-irradiated (2 J/m2) and differen-
tial staining of sister chromatids was achieved by growing LCL in the 
presence of 25 μM BrdU for 48 hours. After 4 hours of treatment in 
Colcemid, cells were swollen in 75 mM KCl for 10 minutes and fixed 
overnight at 4°C with Carnoy’s solution (methanol/acetic acid, 3:1). 
Chromosomes were spread by dropping cells from 40 cm high onto 
frozen slides, which were then left to dry for 3 days. Slides were then 
incubated for 20 minutes in Hoescht (10 μg/ml) in the dark. After 
washing in SSC buffer (2 M NaCl, 0.3 M tri-sodium citrate, pH 7.0) 
slides were irradiated for 1 hour under a UV lamp (355 nm), followed 
by incubation in SCC buffer at 60°C for 1 hour. Slides were finally 
stained with modified Giemsa stain (GS500; Sigma-Aldrich).
Zebrafish studies. WT TLF zebrafish (Danio rerio) were maintained 
and raised using standard protocols (43) in accordance with UK Home 
Office guidelines. Two splice-blocking MOs, nsmce2 sp1 and nsmce2 
sp2, were designed to knock down nsmce2 expression (GeneTools, 
Philomath) (Supplemental Table 4 and Supplemental Figure 5). nsmce2 
sp1 and nsmce2 sp2 were tested independently for effectiveness (data 
not shown) and then used in combination at a 1:1 ratio (data reported 
here). One- to two-cell embryos obtained from natural matings were 
microinjected with 1.8 nl of a 0.55 mM nsmce2 sp1 and 2 cocktail solu-
tion or the same concentration of control MO (Supplemental Table 3). 
Uninjected embryos were kept for comparison.
The efficiency of knockdown was assessed by PCR on cDNA 
derived from morphant or control embryos collected at day 2. mRNA 
was extracted using TRIzol (Invitrogen). One microgram of mRNA 
from each group was transcribed using Superscript II First Strand Syn-
thesis System (Invitrogen). Specific primers were then used to ampli-
fy a region across exons 1–3 for nsmce2 sp1 and across exons 2–4 for 
nsmce2 sp2 as well as control primers for Agpat2 to check equal load-
ing. Primers are detailed in Supplemental Table 3.
Embryos were cultured in egg water at 28.5°C for 48 hours before 
scoring phenotypes. Live fish images were captured using a Leica M80 
stereomicroscope, and body length was calculated by the Leica Appli-
cation Suite program. Embryos were assigned to categories defined 
with reference to the SD of the length of a population of uninjected WT 
fish from the same mating. The experiment was carried out 6 times. 
Data shown are representative. For rescue experiments capped full-
length human NSMCE2 mRNA (either WT, S116Lfs*18, A234Efs*4, 
or SUMO LD) was transcribed in vitro following the manufacturer’s 
manual (mMessage mMachine; Invitrogen). RNA was purified using 
a Megaclear column (Ambion) and quantified spectrophotometrically 
and the size verified on an agarose gel. 100 picograms of mRNA were 
comicroinjected with nsmce2/mms21 MO at the 1- to 2-cell stage and 
the phenotype scored after 48 hours.
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